At the time of writing, Supernus Pharmaceuticals Inc [SUPN] stock is trading at $32.10, up 1.97%. Until recently, the best way to gauge how the stock has performed was to look at its short-term value. The SUPN shares have gain 11.54% over the last week, with a monthly amount glided 12.67%, and seem to be holding up well over a long-time horizon.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
From an analyst’s perspective:
On April 13, 2021, upgrade upgraded it’s rating to Buy and revised its price target to $40 on the stock. Piper Sandler upgraded its rating to a Overweight and increased its price target to $31 on June 16, 2020. Berenberg downgraded its rating to Hold for this stock on November 08, 2019. In a note dated November 07, 2019, Stifel downgraded an Hold rating on this stock and revised its target price from $55 to $23.
For the past year, the stock price of Supernus Pharmaceuticals Inc fluctuated between $21.99 and $35.44. Currently, Wall Street analysts expect the stock to reach $39.67 within the next 12 months. Supernus Pharmaceuticals Inc [NASDAQ: SUPN] shares were valued at $32.10 at the most recent close of the market. An investor can expect a potential return of 23.58% based on the average SUPN price forecast.
Analyzing the SUPN fundamentals
According to Supernus Pharmaceuticals Inc [NASDAQ:SUPN], the company’s sales were 630.16M for trailing twelve months, which represents an 24.17% jump. Gross Profit Margin for this corporation currently stands at 0.78% with Operating Profit Margin at 0.07%, Pretax Profit Margin comes in at 0.06%, and Net Profit Margin reading is 0.01%. To continue investigating profitability, this company’s Return on Assets is posted at 0.0, Equity is 0.01 and Total Capital is 0.04. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of0.04.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 31.57 points at the first support level, and at 31.04 for the second support level. However, for the 1st resistance point, the stock is sitting at 32.52, and for the 2nd resistance point, it is at 32.94.
Ratios To Look Out For
It is important to note that Supernus Pharmaceuticals Inc [NASDAQ:SUPN] has a current ratio of 1.91. As well, the Quick Ratio is 1.69, while the Cash Ratio is 0.17. Considering the valuation of this stock, the price to sales ratio is 2.81, the price to book ratio is 1.85 and price to earnings (TTM) ratio is 363.53.
Transactions by insiders
Recent insider trading involved TAMI TILLOTSON MARTIN, Former Officer, that happened on Aug 02 ’24 when 4000.0 shares were purchased. Former Officer, TAMI TILLOTSON MARTIN completed a deal on Aug 01 ’24 to buy 3100.0 shares. Meanwhile, Former Officer TAMI TILLOTSON MARTIN bought 5000.0 shares on Jul 31 ’24.
